AT6

Target: AT6 selectively targets BRD4 as an analog of the AT 1 degrader.

Binding site: Its BRD4 ligand binds the bromodomain acetyl-lysine recognition pocket.

Mechanism of action: AT6 is an analog of the BRD4 degrader AT 1, retaining a bifunctional architecture that connects a BRD4-binding ligand to a VHL-recruiting ligand. This design promotes induced proximity between BRD4 and the VHL E3 ligase complex, enabling ubiquitination and proteasome-mediated depletion of BRD4 protein. As a structurally related probe, AT6 can support comparative studies of linker composition, ternary-complex geometry, and BRD4 degradation selectivity. It is useful for evaluating how changes around an established BRD4 PROTAC scaffold affect degradation efficiency and BET-family selectivity.

• PROTAC-Mediated Kinase Degradation: AT6 is utilized to explore selective degradation of kinases, offering insights into kinase-related signaling pathways. By targeting specific kinases for degradation, researchers can dissect complex cellular processes and identify novel therapeutic targets.

• Targeted Protein Degradation in Oncology: AT6 facilitates the study of oncogenic protein degradation, aiding in the investigation of cancer cell survival mechanisms. This approach enables the elucidation of protein roles in tumorigenesis, potentially leading to the discovery of new anti-cancer strategies.

• Drug Resistance Mechanism Studies: Utilizing AT6 in research allows for the examination of drug resistance mechanisms through targeted degradation of resistance-conferring proteins. This application is crucial for developing strategies to overcome resistance in various disease models.

• PROTAC-Based Tool Development: AT6 serves as a valuable tool in the development of next-generation PROTACs, providing a model for optimizing degradation efficiency and selectivity. Researchers can leverage this product to enhance the design of more effective protein degraders.